Subtype
Esophageal Carcinoma
CI-CAN-00002609ESCAExplore in graph →
307 active trials4 approved drugs11 evidence items
- NCIt
- C3513
- DOID
- 1107
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00002609ESCAExplore in graph →
Clinical trials
807 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (62)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc. |
| 1 |
| Mar 26, 2025 |
| clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06289374 | Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery(LABS) | recruiting | — | 100 | Imperial College LondonOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05937438 | Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | recruiting | Phase 1 / Phase 2 | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05214222 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma(ANSWER) | recruiting | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06710665 | Tumor Regression Grade As Predictor of Adjuvant Therapy | recruiting | — | 400 | Fujian Medical University Union HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | recruiting | Phase 2 | 188 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06690476 | Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma | recruiting | Early Phase 1 | 74 | Peking UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05919030 | A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 155 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06022861 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 510 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602843 | Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy | recruiting | N/A | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06561178 | Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401) | recruiting | — | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06408584 | Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab(SCHRT) | recruiting | — | 25 | Anhui Provincial HospitalOTHER_GOV | 1 | May 21, 2024 | clinicaltrials |
| NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | recruiting | Phase 3 | 354 | Fudan UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06187597 | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)(EC-CRT-007) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05833594 | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT03964753 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma(NTNC) | recruiting | Phase 2 | 202 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06056336 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 73 | Guo XufengOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05952661 | Minimally Residual of Esophageal Cancer 001(ECMRD-001) | recruiting | — | 56 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05740995 | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | recruiting | — | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05775419 | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC | recruiting | N/A | 1,216 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00574327 | Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry | recruiting | — | 3,000 | Midwest Biomedical ResearchOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04652180 | Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .(CIR·ROB) | recruiting | N/A | 108 | Hospital Universitari de BellvitgeOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05252078 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients(ALTER-E005) | recruiting | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05642338 | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study(WATSEURO2) | recruiting | — | 416 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2025source: clinicaltrials